Literature DB >> 27175968

MicroRNA‑126 is downregulated in thyroid cancer cells, and regulates proliferation, migration and invasion by targeting CXCR4.

Yan Qian1, Xiaoli Wang2, Zhanlu Lv1, Chen Guo1, Yongjian Yang3, Jinliang Zhang1, Xianliang Wang1.   

Abstract

MicroRNA-126 (miR-126) has previously been reported to be downregulated in various types of cancer; however, at present, there are no studies of miR‑126 in human thyroid cancer. The present study aimed to determine the expression and effects of miR‑126 on thyroid cancer. The expression levels of miR‑126 were detected in human thyroid cancer tissues, matched normal adjacent tissues and human thyroid cancer cell lines using quantitative polymerase chain reaction. In addition, post‑transfection of human thyroid cancer cells with miR‑126 mimics, cell proliferation, migration and invasion assays, western blot analysis and luciferase assays were conducted. The results demonstrated that miR‑126 was downregulated in thyroid cancer tissues and cells. Furthermore, upregulation of miR‑126 inhibited cell proliferation, migration and invasion in thyroid cancer cells. The present study also provided evidence suggesting that miR‑126 may directly target C‑X‑C chemokine receptor type 4 (CXCR4) in thyroid cancer. These results indicated that miR‑126 may be investigated as a target for the treatment of thyroid cancer.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27175968     DOI: 10.3892/mmr.2016.5276

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  9 in total

1.  Overexpression miR-211-5p hinders the proliferation, migration, and invasion of thyroid tumor cells by downregulating SOX11.

Authors:  Lei Wang; Yan-Feng Shen; Zhi-Min Shi; Xiao-Juan Shang; Dong-Ling Jin; Feng Xi
Journal:  J Clin Lab Anal       Date:  2017-07-13       Impact factor: 2.352

Review 2.  MicroRNAs as the critical regulators of cell migration and invasion in thyroid cancer.

Authors:  Amir Abbas Hamidi; Negin Taghehchian; Zahra Basirat; Amir Sadra Zangouei; Meysam Moghbeli
Journal:  Biomark Res       Date:  2022-06-04

3.  MicroRNA-139 targets fibronectin 1 to inhibit papillary thyroid carcinoma progression.

Authors:  Ying Ye; Juhua Zhuang; Guoyu Wang; Saifei He; Jing Ni; Wei Xia
Journal:  Oncol Lett       Date:  2017-10-17       Impact factor: 2.967

4.  MicroRNA Expression in Malignant Pleural Mesothelioma and Asbestosis: A Pilot Study.

Authors:  Paola Mozzoni; Luca Ampollini; Matteo Goldoni; Rossella Alinovi; Marcello Tiseo; Letizia Gnetti; Paolo Carbognani; Michele Rusca; Antonio Mutti; Antonio Percesepe; Massimo Corradi
Journal:  Dis Markers       Date:  2017-07-03       Impact factor: 3.434

5.  Genome-scale analysis to identify prognostic microRNA biomarkers in patients with early stage pancreatic ductal adenocarcinoma after pancreaticoduodenectomy.

Authors:  Xiwen Liao; Xiangkun Wang; Ketuan Huang; Chengkun Yang; Tingdong Yu; Chuangye Han; Guangzhi Zhu; Hao Su; Rui Huang; Tao Peng
Journal:  Cancer Manag Res       Date:  2018-08-10       Impact factor: 3.989

6.  lncRNA HOTAIR promotes gastric cancer proliferation and metastasis via targeting miR-126 to active CXCR4 and RhoA signaling pathway.

Authors:  Jun Xiao; Hao Lai; Sheng-Hong Wei; Zai-Sheng Ye; Fu-Sheng Gong; Lu-Chuan Chen
Journal:  Cancer Med       Date:  2019-09-13       Impact factor: 4.452

7.  Knockdown of circPVT1 inhibits progression of papillary thyroid carcinoma by sponging miR-126.

Authors:  Ling Tao; Li Yang; Ping Tian; Xiangyang Guo; Yanping Chen
Journal:  RSC Adv       Date:  2019-04-30       Impact factor: 3.361

8.  LINC00888 promoted tumorigenicity of melanoma via miR-126/CRK signaling axis.

Authors:  Wei Lu; Xiaohua Tao; Yibin Fan; Yi Tang; Xin Xu; Shasha Fan; Youming Huang; Yong Yu; Dan Luo
Journal:  Onco Targets Ther       Date:  2018-07-31       Impact factor: 4.147

9.  hsa-miR-195-5p inhibits cell proliferation of human thyroid carcinoma cells via modulation of p21/cyclin D1 axis.

Authors:  Dexin Liu; Ping Li; Xiaodong Wang; Wei Wang
Journal:  Transl Cancer Res       Date:  2020-09       Impact factor: 1.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.